What is Microbion?
Founded in 2000, Microbion operates at the intersection of advanced microbiology and pharmacology. The company is primarily focused on the development of a novel class of microbial bioenergetic inhibitors, a therapeutic approach designed to combat difficult-to-treat and resistant bacterial infections. By targeting the fundamental energy processes of pathogens, Microbion distinguishes itself from traditional antibiotic development, offering a unique mechanism of action that addresses the urgent, unmet medical need for effective treatments against multi-drug resistant organisms. Its strategic location in Montana supports a focused research environment, allowing the firm to maintain a lean, high-impact operational model while collaborating with global health organizations and institutional investors.
How much funding has Microbion raised?
Microbion has raised a total of $46.5M across 6 funding rounds:
Private Equity
$932K
Private Equity
$1.2M
Unspecified
$100K
Private Equity
$25M
Other Financing Round
$17.1M
Private Equity
$2.1M
Private Equity (2010): $932K, investors not publicly disclosed
Private Equity (2012): $1.2M, investors not publicly disclosed
Unspecified (2014): $100K supported by Undisclosed
Private Equity (2016): $25M featuring GF Securities and Quark Venture
Other Financing Round (2020): $17.1M backed by Cystic Fibrosis Foundation and Carb-X
Private Equity (2022): $2.1M with participation from MTEC companies
Key Investors in Microbion
Cystic Fibrosis Foundation
A prominent 501 non-profit organization dedicated to curing cystic fibrosis and improving the quality of life for those affected by the disease.
Carb-X
A global non-profit partnership that accelerates antibacterial innovation by funding early-stage development of new antibiotics and rapid diagnostics.
MTEC companies
A biomedical research consortium that facilitates the rapid deployment of innovative medical technologies for both military and civilian health applications.
What's next for Microbion?
With the infusion of this recent capital, Microbion is positioned to accelerate its clinical trial programs and expand its research infrastructure. The company's strategic roadmap involves navigating complex regulatory pathways to bring its bioenergetic inhibitors to market, a move that could redefine the standard of care for chronic and acute resistant infections. As the firm continues to leverage its partnerships with organizations like the Cystic Fibrosis Foundation and CARB-X, the focus will shift toward scaling manufacturing capabilities and finalizing late-stage clinical data. This phase is critical for validating the long-term efficacy of their platform, potentially setting the stage for future commercialization or strategic licensing agreements within the broader biotechnology landscape.
See full Microbion company page
